Jeff Davis joined Acer as Chief Business Officer in February 2021. Mr. Davis is a veteran life science executive and transaction specialist with over 25 years of experience in business and corporate development. Mr. Davis has led or supported over 40 transactions with an aggregate value more than $2B across all major therapeutic platforms, including antibodies, small molecules, aptamers, gene therapy, vaccines, and proteins.
He most recently served as the Vice President of Corporate Development for Censa Pharmaceuticals prior to their acquisition by PTC Therapeutics. Prior to Censa, he was a Partner at Extera Partners, acting Chief Business Officer for Acer Therapetuics, and was a co-founder of Censa Pharmaceuticals and Atacama Therapeutics. In addition, Mr. Davis held senior business and corporate development roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly. Jeff started his career at Sphinx Pharmaceuticals (acquired by Eli Lilly) as a Biochemist. Mr. Davis received a BS in Biochemistry from North Carolina State University and an MBA from Duke University.